HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Efficacy of clonidine in opiate withdrawal: a study of thirty patients.

AbstractIn a placebo-controlled, double-blind crossover trial, clonidine caused a marked and significant reduction of objective signs and subjective symptoms of opiate withdrawal in thirty hospitalized opiate addicts. In an open trial of clonidine in opiate withdrawal, clonidine was found to suppress opiate withdrawal signs and symptoms, allowing all of the patients to detoxify successfully from chronic opiate addiction. Clonidine was demonstrated to reverse and suppress the signs, symptoms, and effects associated with opiate withdrawal. These data support a release from chronic opiate-induced noradrenergic inhibition producing noradrenergic hyperactivity as the pathophysiological substrate for opiate withdrawal. Clonidine replaces opiate-mediated inhibition with alpha-2 mediated inhibition of noradrenergic nuclei.
AuthorsM S Gold, A L Pottash, D R Sweeney, H D Kleber
JournalDrug and alcohol dependence (Drug Alcohol Depend) Vol. 6 Issue 4 Pg. 201-8 (Oct 1980) ISSN: 0376-8716 [Print] SWITZERLAND
PMID7023893 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Narcotics
  • Clonidine
Topics
  • Brain (drug effects)
  • Clinical Trials as Topic
  • Clonidine (administration & dosage, pharmacology, therapeutic use)
  • Double-Blind Method
  • Humans
  • Narcotics (adverse effects)
  • Substance Withdrawal Syndrome (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD